Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor

Research output: Conference materialsAbstractResearchpeer-review

Abstract

Immunotherapy relies on the involvement of the patient’s immune system to control the growth of the tumor by, e.g., the administration of immune checkpoint inhibitors, has recently led to increased long-term survival in cancer patients. Amongst the different immunotherapies evaluated in the last years, cancer vaccines are investigated as tools to prime tumor-specific immunity. Biomaterials and, particularly, nano-sized particles, have demonstrated potential as adjuvants in vaccine formulations. The choice of the proper antigenic source is of the uttermost importance for a widespread action against cancer: lately, biomimetic elements derived from the membrane of tumors cells have been evaluated as innovative antigenic sources. Here, we developed a biohybrid cancer nanovaccine and assessed its efficacy in aggressive murine melanoma tumor models in vivo. Porous silicon nanoparticles coated with acetalated dextran formed the core of the formulation that was enriched with the antigenic component through a coating derived from tumor cell membranes [1]. The nanovaccine is cytocompatible and promoted the maturation of murine antigen presenting cells in vitro. Moreover, mice treated twice with the complete nanovaccine formulation showed remissions and control on the tumor progression: the immunological profile of the tumor microenvironment was modified, augmenting the number of mature dendritic cells. We also investigated the effect of a combinatorial therapy with the administration of anti-CTLA4 checkpoint inhibitor together with the biohybrid nanovaccine. The combo therapy results in a synergistic effect, improving the efficacy of both treatments (87.5% of the animals responding, with 2 remissions), reflected also in an increased number of cytotoxic lymphocytes in the tumor microenvironment. This platform thereby shows very promising applications as cancer nanovaccine and promoting a synergistic effect with the standard clinical care treatment for melanoma cancers.

References
[1] Fontana. F (2017), Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy, Adv Mater, 29, 1603239.

Original languageEnglish
Publication statusPublished - 2017
Event4th Meeting of the French Society of Nanomedicine 2017 - BORDEAUX INP / ENSEIRB-MatMeca, Avenue des facultés, Talence, France
Duration: 5 Dec 20177 Dec 2017
http://www.sfnano.fr/bordeaux-2017/

Conference

Conference4th Meeting of the French Society of Nanomedicine 2017
Abbreviated titleSFNano Bordeaux 2017
CountryFrance
CityTalence
Period05/12/201707/12/2017
Internet address

Fields of Science

  • 317 Pharmacy
  • Nanotechnology
  • Immunotherapy
  • Cancer
  • Vaccine

Cite this

Fontana, F., Capasso, C., Fusciello, M., Feola, S., Mäkilä, E., Salonen, J., ... Almeida Santos, H. (2017). Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor. Abstract from 4th Meeting of the French Society of Nanomedicine 2017, Talence, France.
@conference{88fc062897634214b518e0be629f7699,
title = "Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor",
abstract = "Immunotherapy relies on the involvement of the patient’s immune system to control the growth of the tumor by, e.g., the administration of immune checkpoint inhibitors, has recently led to increased long-term survival in cancer patients. Amongst the different immunotherapies evaluated in the last years, cancer vaccines are investigated as tools to prime tumor-specific immunity. Biomaterials and, particularly, nano-sized particles, have demonstrated potential as adjuvants in vaccine formulations. The choice of the proper antigenic source is of the uttermost importance for a widespread action against cancer: lately, biomimetic elements derived from the membrane of tumors cells have been evaluated as innovative antigenic sources. Here, we developed a biohybrid cancer nanovaccine and assessed its efficacy in aggressive murine melanoma tumor models in vivo. Porous silicon nanoparticles coated with acetalated dextran formed the core of the formulation that was enriched with the antigenic component through a coating derived from tumor cell membranes [1]. The nanovaccine is cytocompatible and promoted the maturation of murine antigen presenting cells in vitro. Moreover, mice treated twice with the complete nanovaccine formulation showed remissions and control on the tumor progression: the immunological profile of the tumor microenvironment was modified, augmenting the number of mature dendritic cells. We also investigated the effect of a combinatorial therapy with the administration of anti-CTLA4 checkpoint inhibitor together with the biohybrid nanovaccine. The combo therapy results in a synergistic effect, improving the efficacy of both treatments (87.5{\%} of the animals responding, with 2 remissions), reflected also in an increased number of cytotoxic lymphocytes in the tumor microenvironment. This platform thereby shows very promising applications as cancer nanovaccine and promoting a synergistic effect with the standard clinical care treatment for melanoma cancers.References[1] Fontana. F (2017), Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy, Adv Mater, 29, 1603239.",
keywords = "317 Pharmacy, Nanotechnology, Immunotherapy, Cancer, Vaccine",
author = "Flavia Fontana and Cristian Capasso and Manlio Fusciello and Sara Feola and Ermei M{\"a}kil{\"a} and Jarno Salonen and Hirvonen, {Jouni Tapio} and Vincenzo Cerullo and {Almeida Santos}, Helder",
year = "2017",
language = "English",
note = "4th Meeting of the French Society of Nanomedicine 2017, SFNano Bordeaux 2017 ; Conference date: 05-12-2017 Through 07-12-2017",
url = "http://www.sfnano.fr/bordeaux-2017/",

}

Fontana, F, Capasso, C, Fusciello, M, Feola, S, Mäkilä, E, Salonen, J, Hirvonen, JT, Cerullo, V & Almeida Santos, H 2017, 'Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor' 4th Meeting of the French Society of Nanomedicine 2017, Talence, France, 05/12/2017 - 07/12/2017, .

Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor. / Fontana, Flavia; Capasso, Cristian; Fusciello, Manlio; Feola, Sara; Mäkilä, Ermei; Salonen, Jarno; Hirvonen, Jouni Tapio; Cerullo, Vincenzo; Almeida Santos, Helder.

2017. Abstract from 4th Meeting of the French Society of Nanomedicine 2017, Talence, France.

Research output: Conference materialsAbstractResearchpeer-review

TY - CONF

T1 - Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor

AU - Fontana, Flavia

AU - Capasso, Cristian

AU - Fusciello, Manlio

AU - Feola, Sara

AU - Mäkilä, Ermei

AU - Salonen, Jarno

AU - Hirvonen, Jouni Tapio

AU - Cerullo, Vincenzo

AU - Almeida Santos, Helder

PY - 2017

Y1 - 2017

N2 - Immunotherapy relies on the involvement of the patient’s immune system to control the growth of the tumor by, e.g., the administration of immune checkpoint inhibitors, has recently led to increased long-term survival in cancer patients. Amongst the different immunotherapies evaluated in the last years, cancer vaccines are investigated as tools to prime tumor-specific immunity. Biomaterials and, particularly, nano-sized particles, have demonstrated potential as adjuvants in vaccine formulations. The choice of the proper antigenic source is of the uttermost importance for a widespread action against cancer: lately, biomimetic elements derived from the membrane of tumors cells have been evaluated as innovative antigenic sources. Here, we developed a biohybrid cancer nanovaccine and assessed its efficacy in aggressive murine melanoma tumor models in vivo. Porous silicon nanoparticles coated with acetalated dextran formed the core of the formulation that was enriched with the antigenic component through a coating derived from tumor cell membranes [1]. The nanovaccine is cytocompatible and promoted the maturation of murine antigen presenting cells in vitro. Moreover, mice treated twice with the complete nanovaccine formulation showed remissions and control on the tumor progression: the immunological profile of the tumor microenvironment was modified, augmenting the number of mature dendritic cells. We also investigated the effect of a combinatorial therapy with the administration of anti-CTLA4 checkpoint inhibitor together with the biohybrid nanovaccine. The combo therapy results in a synergistic effect, improving the efficacy of both treatments (87.5% of the animals responding, with 2 remissions), reflected also in an increased number of cytotoxic lymphocytes in the tumor microenvironment. This platform thereby shows very promising applications as cancer nanovaccine and promoting a synergistic effect with the standard clinical care treatment for melanoma cancers.References[1] Fontana. F (2017), Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy, Adv Mater, 29, 1603239.

AB - Immunotherapy relies on the involvement of the patient’s immune system to control the growth of the tumor by, e.g., the administration of immune checkpoint inhibitors, has recently led to increased long-term survival in cancer patients. Amongst the different immunotherapies evaluated in the last years, cancer vaccines are investigated as tools to prime tumor-specific immunity. Biomaterials and, particularly, nano-sized particles, have demonstrated potential as adjuvants in vaccine formulations. The choice of the proper antigenic source is of the uttermost importance for a widespread action against cancer: lately, biomimetic elements derived from the membrane of tumors cells have been evaluated as innovative antigenic sources. Here, we developed a biohybrid cancer nanovaccine and assessed its efficacy in aggressive murine melanoma tumor models in vivo. Porous silicon nanoparticles coated with acetalated dextran formed the core of the formulation that was enriched with the antigenic component through a coating derived from tumor cell membranes [1]. The nanovaccine is cytocompatible and promoted the maturation of murine antigen presenting cells in vitro. Moreover, mice treated twice with the complete nanovaccine formulation showed remissions and control on the tumor progression: the immunological profile of the tumor microenvironment was modified, augmenting the number of mature dendritic cells. We also investigated the effect of a combinatorial therapy with the administration of anti-CTLA4 checkpoint inhibitor together with the biohybrid nanovaccine. The combo therapy results in a synergistic effect, improving the efficacy of both treatments (87.5% of the animals responding, with 2 remissions), reflected also in an increased number of cytotoxic lymphocytes in the tumor microenvironment. This platform thereby shows very promising applications as cancer nanovaccine and promoting a synergistic effect with the standard clinical care treatment for melanoma cancers.References[1] Fontana. F (2017), Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy, Adv Mater, 29, 1603239.

KW - 317 Pharmacy

KW - Nanotechnology

KW - Immunotherapy

KW - Cancer

KW - Vaccine

M3 - Abstract

ER -

Fontana F, Capasso C, Fusciello M, Feola S, Mäkilä E, Salonen J et al. Biohybrid Nanovaccines in Murine Melanoma: Efficacy and Synergistic Combo Therapy with Immune Checkpoint Inhibitor. 2017. Abstract from 4th Meeting of the French Society of Nanomedicine 2017, Talence, France.